VeronaPharmaplcNASDAQ_VRNA_202310-K.pdf

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF1934For the fiscal year ended December 31,2023OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACTOF 1934FOR THE TR

2、ANSITION PERIOD FROM _ TO _Commission File Number:001-38067Verona Pharma plc(Exact name of Registrant as specified in its Charter)United Kingdom98-1489389(State or other jurisdiction of incorporation or organization)(I.R.S.Employer Identification No.)3 More London RiversideLondon SE1 2RE United King

3、domNot Applicable(Address of principal executive offices)(Zip Code)Registrants telephone number,including area code:+44 203 283 4200Securities registered pursuant to Section 12(b)of the Act:Title of each classTrading SymbolName of each exchange on which registeredOrdinary shares,nominal value 0.05 p

4、er share*VRNAThe Nasdaq Stock Market LLC(Nasdaq Global Market)*The ordinary shares are represented by American Depositary Shares(each representing 8 ordinary shares),which are exempt from the operation of Section 12(a)of the SecuritiesExchange Act of 1934,as amended,pursuant to Rule 12a-8 thereunder

5、.Securities registered pursuant to Section 12(g)of the Act:NoneIndicate by check mark if the Registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d)of the A

6、ct.Yes No Indicate by check mark whether the Registrant:(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of1934 during the preceding 12 months(or for such shorter period that the Registrant was required to file such reports),and(2)has been subject to